Vetter Continues to Strengthen its Market Position
Vetter, a leading contract development and manufacturing organisation for pre-filled application systems, has announced that 2013 was yet another growth year for the company.
As evidenced by a growing demand for customer projects in clinical phases and commercial aseptic manufacturing, the CDMO increased sales by more than 10%. Currently the company employs around 3300 people at its German and US facilities. This sustained, positive development by the company was made possible as a result of its high quality and safety standards, as well as investments made across the company’s facilities for process optimisation.
With an increase in market demand, Vetter responded by strengthening and reinforcing its position as a strategic partner for both the development phase, and commercial manufacturing of parenteral drugs. These actions included the increase in its capacities and service portfolio in production sites in Germany and the US.
The company is planning the implementation of three new filling lines and is also making investments in innovative technologies. Vetter will also continue to optimise its quality management and processes in manufacturing and logistics to support pharmaceutical and biotech companies in meeting market requirements of quality and safety.
Another reason for the strong growth is the newly launched customer projects at Vetter’s Chicago site. Here the company supports its customers in process development and manufacturing of clinical trials during product development. Once the clinical development phases are completed, the product it transferred to the German facilities for commercial production and market supply.
"Increasingly, our customers rely on our expertise and more than 35 years of experience in aseptic filling of injection systems," said Vetter Managing Director Peter Soelkner. “Next to a reliable production for continuous market supply, we also supported our customers with their complex development projects with our Development Service both in Chicago and Ravensburg."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance